Focus Stocks
New Ratings
Published on Tuesday, 27 November 2012 07:57 Written by Danny Miller
New York, November 27th (TradersHuddle.com) – Following are some of the new analyst ratings before the market open.
Research Firms Initiate:
Amarin Corporation (NASDAQ: AMRN) was initiated with a Buy at Citigroup.
Angie's List (NASDAQ: ANGI) was initiated with Outperform at Northland Securities.
Crocs Inc (NASDAQ: CROX) was initiated with a Buy at Goldman Sachs.
Deckers Outdoor (NASDAQ: DECK) was initiated with a Neutral at Goldman Sachs.
Delek Logistics Partners (NYSE: DKL) was initiated with Overweight at Barclays and with a Buy at Goldman Sachs.
Finish Line (NASDAQ: FINL) was initiated with a Neutral at Goldman Sachs.
Foot Locker (NYSE: FL) was initiated with a Buy at Goldman Sachs.
Jazz Pharmaceuticals (NASDAQ: JAZZ) was initiated with a Buy at Citigroup.
NCR Corp. (NYSE: NCR) was initiated with a Positive at Susquehanna.
Restoration Hardware (NYSE: RH) was initiated with a Neutral at Bank of America Merrill and with Overweight at Piper Jaffray.
Steve Madden (NASDAQ: SHOO) was initiated with a Sell at Goldman Sachs.
Wolverine World Wide (NYSE: WWW) was initiated with a Neutral at Goldman Sachs.
Related Articles
- Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R)
- Angie's List, Inc. Announces First Quarter 2013 Financial Results Conference Call
- Angie's List Announces Departure of Robert R. Millard, Chief Financial Officer
- Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa(R) and Planned ANCHOR Indication
- Amarin Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Update on Operations
- Angie's List to Present at Deutsche Bank's dbAccess Media, Internet & Telecom Conference
- Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia
- Amarin to Report Fourth Quarter and Year-End 2012 Results and Host Conference Call on February 28, 2013
- Amarin to Present at the CITI 2013 Global Healthcare Conference
- Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,129 Related to Vascepa(R) and FDA Approved MARINE Indication
Related Partner Headlines
- First 90 Days of 2013 Are Live or Die For These Biotech Stocks - TheStreet.com
- Amarin Receives Patent Allowance for App Related to Vascepa, FDA-Approved MARINE - Benzinga
- Benzinga's M&A Chatter for Friday November 16, 2012 - Benzinga
- Amarin Pushed Closer to Solo Vascepa Launch By Another NCE Delay - TheStreet.com
- Deckers Higher as Jefferies Note Calling Co. Takeover Target Getting Passed Around - Benzinga
- Hot Biotech Stocks Traded By Hedge Funds in Third Quarter - TheStreet.com
- Deckers Outdoor Corporation (DECK): Today's Featured Consumer Goods Winner - TheStreet.com
- Mid-Morning Market Update: Markets Rallying; J.C. Penney Misses Big On Earnings - Benzinga
- Toyota Motor Corporation and More Big Movers in Consumer Cyclical on November 5, 2012 - Investopedia
- Top 4 Small-Cap Stocks In The Textile-Apparel Footwear & Accessories Industry With The Highest ROA - Benzinga
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
